Boehringer Mannheim Gmbh

Hoffmann-la Roche Inc.

Roche Diagnostics Gmbh

Roche Diagnostics Operations, Inc.

Roche Palo Alto LLC

F. Hoffmann-la Roche Ag

Josef Endl

Winfried Albert

Michael Brandt

Herbert Jungfer

Erhard Kopetzki

Georg Tiefenthaler

Rosemarie Kientsch-Engel

Hartmut Schetters

Wiltrud Richter

Oliver Ploettner

Ursula Schwarz

Werner Scherbaum

Thomas Eiermann

Paul Parren

Stefan Seeber

Joerg Thomas Regula

Jan Van De Winkel

Kay-Gunnar Stubenrauch

Ralf Schumacher

Dolores Schendel

Adelbert Grossmann

Yvo Graus

Martin Lanzendoerfer

Martine Van Vugt

Frank Rebers

Sonja Offner

Peter Stahl

Josef Platzer

Jan Olaf Stracke

Sebastian Neumann

Maria Elena Fuentes

Peter Kern

Guenther-Gerhard Jung

Verena Litty

Thomas Wild

Klaus Dornmair

Edgar Meinl

Sandra Vereecken-Verploegen

Suzanne Elisabeth Berlo

Jan Stracke

Aran Labrijn

Basile Siewe

Irmgard Thorey

Natalie Herr

Elsie Eugui

Maria Fuentes

Natalie Schuhmacher

The current invention describes a nucleic acid comprising in a 5' to 3&#x2032; direction a) a first nucleic acid encoding a heterologous polypeptide without an in frame stop codon, b) a second nucleic acid beginning with a 5&#x2032; splice donor site and terminated by a 3&#x2032; splice acceptor site comprising an in frame translational stop codon and a polyadenylation signal, and c) a nucleic acid encoding i) at least a fragment of a transmembrane domain, or ii) a signal peptide for a GPI-anchor.

Polypeptide producing cells

The instant specification discloses an antibody binding to IL-13R&#x3b1;1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of this antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9, and this antibody is useful in the treatment of asthma and allergic diseases.

Antibodies against IL-13 receptor alpha1 and uses thereof

The invention concerns autoreactive peptides, peptide-MHC complexes, T cell subpopulations that react thereto as well as diagnostic and therapeutic applications of these compounds.

Antigen-specific, activated T lymphocytes, detection and use

The invention concerns human monoclonal antibodies to the islet cell antigen IA-2, a process for their production, the use of human monoclonal antibodies in a method for detecting antibodies to IA-2, a method for detecting antibodies to the islet cell antigen IA-2 and a method for detecting the islet cell antigen IA-2 in a sample.

Human monoclonal antibodies to the islet cell antigen IA-2

The invention concerns human monoclonal antibodies of the IgG isotype against human pancreatic islet cells which can be obtained by immortalizing human lymphocytes of prediabetics or diabetics, treating the culture supernatant of the immortalized cells with a conjugate of antibodies against human Fc &ggr; and a label, subsequently treating with human immunoglobulin, incubating with immobilized human pancreatic islet cells identifying an immortalized human cell culture which produces an antibody against pancreatic islet cells via determination of the label bound to the immobilized islet cells, isolating a human immortalized cell which produces this antibody, propagating this immortalized cell and isolating the monoclonal antibody produced by these cells. The invention also concerns a process for the isolation of an islet cell antigen to which such antibodies bind as well as a method for the determination of antibodies against an islet cell antigen of the pancreas.

Monoclonal antibodies of isotype IgG which bind specifically to glutamate decarboxylase, and uses thereof

The invention concerns human monoclonal antibodies of the IgG isotype against human pancreatic islet cells which can be obtained by immortalizing human lymphocytes of prediabetics or diabetics, treating the culture supernatant of the immortalized cells with a conjugate of antibodies against human Fc .gamma. and a label, subsequently treating with human immunoglobulin, incubating with immobilized human pancreatic islet cells identifying an immortalized human cell culture which produces an antibody against pancreatic islet cells via determination of the label bound to the immobilized islet cells, isolating a human immortalized cell which produces this antibody, propagating this immortalized cell and isolating the monoclonal antibody produced by these cells. The invention also concerns a process for the isolation of an islet cell antigen to which such antibodies bind as well as a method for the determination of antibodies against an islet cell antigen of the pancreas.

Monoclonal antibodies against human pancreatic islet cells

The present invention provides a human monoclonal antibody against melanoma, characterized in that it binds to the gangliosides GM3 and GD3 but essentially does not bind to the gangliosides GM1, GM2, GD1a, GD1b and GD2, the binding of the antibody to the gangliosides having been determined by immune staining after thin layer chromatographic separation of the gangliosides. The present invention also provides a process for the production of human monoclonal antibodies directed against melanoma, wherein, without previous immunization, B-lymphocytes are isolated from a healthy person, the isolated B-lymphocytes are immortalized, antibodies from the immortalized B-lymphocytes are screened by immune-histochemical analysis for binding against melanoma and/or melanoma metastases, the positively reacting B-lymphocytes are selected, cultured and monoclonal antibodies obtained therefrom.

Monoclonal antibodies against melanoma

A process for quantification of cell populations or subpopulations, by incubating a sample with labelled antibodies directed against characteristic surface antigens of the cell population to be quantified to form labelled antibody/antigen complexes. Standards with known, differing particle concentration and having comparable sedimentation behaviour to the cells to be determined and further, carrying molecules which are directed against the labelled antibody or a part hereof are also incubated with the labelled antibodies. The cells of the sample solution, as well as the particles of the standard solution, are separated off from the excess labelled antibodies and the amount of the labelling is measured not only on the cells but also on the particles. By comparison of the measurement value from the sample with the measurement values from the standard solutions, there is ascertained the number of cells to be determined in the sample. The standard and a reagent kit for carrying out the process are also the subject of this application.

Process for the quantification of cell populations or subpopulations and

A process for quantification of cell populations or subpopulations, by incubating a sample with labelled antibodies directed against characteristic surface antigens of the cell population to be quantified to form labelled antibody/antigen complexes. Standards with known, differing particle concentration and having comparable sedimentation behavior to the cells to be determined and further, carrying molecules which are directed against the labelled antibody or a part hereof are also incubated with the labelled antibodies. The cells of the sample solution, as well as the particles of the standard solution, are separated off from the excess labelled antibodies and the amount of the labelling is measured not only on the cells but also on the particles. By comparison of the measurement value from the sample with the measurement values from the standard solutions, there is ascertained the number of cells to be determined in the sample. The standard and a reagent kit for carrying out the process are also the subject of this application.

Growing community of inventors

Weilheim, Germany

Josef Endl